All In Biotech

BLA 761262 · Abbvie INC

Skyrizi

Risankizumab-Rzaa · Intravenous · Interleukin-23 Antagonist

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jun 16, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

89

36 Phase 3, 18 recruiting

FAERS reports

86,264

57,158 serious, 3,115 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2026.

SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 ) 1.1 Plaque Psoriasis SKYRIZI ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older. 1.3 Crohn’s Disease SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults. 1.4 Ulcerative Colitis SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

Mechanism: Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Risankizumab-rzaa inhibits the release of pro-inflammatory cytokines and chemokines.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SKYRIZI · RISANKIZUMAB-RZAA 600MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Risankizumab" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • psoriasis8,117
  • drug ineffective3,773
  • pain3,387
  • fatigue3,279
  • arthralgia3,261
  • device issue2,933
  • pruritus2,798
  • death2,379
  • surgery2,376
  • fall2,347
  • covid-192,283
  • crohn^s disease2,240

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20161
20181
2019357
20201,931
20214,103
202216,392
202315,176
202414,507
202519,572
202614,223

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Skyrizi* (Risankizumab-Rzaa)

2024 spending

$316M

Beneficiaries

5,557

16,641 claims

Per beneficiary

$56,792

$17,021.30 per unit

View as table
YearSpending
2020$0
2021$76,341,484
2022$251,093,665
2023$289,245,101
2024$315,590,528

Part B: Skyrizi* (Risankizumab-Rzaa*) · HCPCS J2327

2024 spending

$76.7M

Beneficiaries

3,490

8,485 claims

Per beneficiary

$21,983

2024 ASP limit $15.00 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$41,263,286
2024$76,720,174

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 150 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.